In 2013, Hohenforst-Schmidt et al. studied the intratumoral injection of cisplatin in five NSCLC patients with EGFR negative and stage IIIa-IV (1 IIIa, 2 IIIb, 2 IV and out of protocol 1 mammarian IV) cancer. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.